On Monday, Immuneering Corp (NASDAQ: IMRX) opened higher 42.08% from the last sessionbefore settling in for the closing price of $2.02. Price fluctuations for IMRX have ranged from $1.00 to $9.00 over the past 52 weeks.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
A company in the Healthcare sector has dropped its sales by -43.59% annually for the last half of the decade. Company’s average yearly earnings per share was noted -2.06% at the time writing. With a float of $21.00 million, this company’s outstanding shares have now reached $29.27 million.
In an organization with 68 employees, it is important to assess its efficiency. In terms of profitability, gross margin is 100.79%, operating margin of 64.04%, and the pretax margin is 59.38%.
Immuneering Corp (IMRX) Insider Updates
A key investor’s attitude towards the stock of the Biotechnology industry is another important factor to consider. The insider ownership of Immuneering Corp is 29.16%, while institutional ownership is 32.38%. The most recent insider transaction that took place on Apr 01 ’24, was worth 1,160,181. In this transaction 10% Owner of this company sold 400,000 shares at a rate of $2.90, taking the stock ownership to the 2,895,273 shares. Before that another transaction happened on Mar 22 ’24, when Company’s Director bought 2,900 for $2.55, making the entire transaction worth $7,385. This insider now owns 2,900 shares in total.
Immuneering Corp (IMRX) Performance Highlights and Predictions
If we go through the results of last quarter, which was made public on 6/30/2024, the company posted -0.43 earnings per share (EPS) for the quarter, besting the agreed prediction (set at -0.49) by 0.06. Wall Street market experts anticipate that the next fiscal year will bring earnings of -0.43 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around -2.06% per share during the next fiscal year.
Immuneering Corp (NASDAQ: IMRX) Trading Performance Indicators
Check out the current performance indicators for Immuneering Corp (IMRX). In the past quarter, the stock posted a quick ratio of 9.39.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -1.91, a number that is poised to hit -0.55 in the next quarter and is forecasted to reach -1.52 in one year’s time.
Technical Analysis of Immuneering Corp (IMRX)
Let’s dig in a bit further. During the last 5-days, its volume was 43.22 million. That was better than the volume of 2.08 million it reported in year-ago period. As of the previous 9 days, the stock’s Stochastic %D was 70.14%. Additionally, its Average True Range was 0.32.
During the past 100 days, Immuneering Corp’s (IMRX) raw stochastic average was set at 66.08%, which indicates a significant increase from 64.84% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 193.70% in the past 14 days, which was higher than the 119.92% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $1.23, while its 200-day Moving Average is $3.38. However, in the short run, Immuneering Corp’s stock first resistance to watch stands at $3.86. Second resistance stands at $4.85. The third major resistance level sits at $5.87. If the price goes on to break the first support level at $1.85, it is likely to go to the next support level at $0.83.
Immuneering Corp (NASDAQ: IMRX) Key Stats
There are currently 29,653K shares outstanding in the company with a market cap of 85.10 million. Presently, the company’s annual sales total 0 K according to its annual income of -53,470 K. Last quarter, the company’s sales amounted to 0 K and its income totaled -14,080 K.
